Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. The company is headquartered in Emeryville, California and currently employs 351 full-time employees. The company went IPO on 2004-02-19. The firm's products include HEPLISAV-B vaccine and CpG 1018. Its HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted) is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. The company also manufactures and sells CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B. The firm is also engaged in developing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines for indications with unmet medical needs. The company is advancing CpG 1018 adjuvant as a premier vaccine adjuvant with adjuvanted vaccine clinical programs for shingles and Tdap, and through global collaborations, which are focused on adjuvanted vaccines for COVID-19, plague, seasonal influenza, and universal influenza.